We’re proud to announce five new Cooley’s Anemia Foundation Medical Research Fellowships for the 2024-2025 grant cycle. The total amount of funding for the research Fellowships is $250,000. These Fellowship recipients were assessed on the basis of the quality of the scientific content, the academic accomplishments and future promise of the investigator, the quality of […]
*IMPORTANT: The following information is a press release that has been released in advance of the date being presented for peer review* Agios Pharmaceuticals announced Monday that its drug Pyrukynd (mitapivat), an oral pyruvate kinase activator, reached its primary endpoint in a Phase III trial evaluating adults with the blood disorder transfusion-dependent alpha- or beta-thalassemia. […]
We are delighted to share with you TIF’s latest publication for patients living with thalassemia, sickle cell disease (SCD) and other rare anemias and their families entitled ‘Travel Guidance for Patients and Families’.
When Maybelline, the iconic beauty brand behind Maria’s first blush, invited her to star in their “We Speak” disability pride campaign, she seized the opportunity to become the very thing she longed to see as a child—a model proudly representing the thalassemia community.
October 18, 2021 – The 2021 TIF International Conference will be held online Nov. 19-21. Registration is free; for more information, go to: www.tifeducation.org
June 25, 2020 – The Thalassaemia International Federation’s (TIF’s) position statement on COVID-19 and Thalassemia has just been published in the European Journal of Haematology. You can access the position statement here: https://www.thalassemia.org/wp-content/uploads/2020/06/COVID-19-and-Thalassaemia-A-Position-Statement-of-the-Thalassaemia-Int….pdf The article notes that “The optimization of blood use will help safeguard blood supplies during the pandemic…One particular aspect of optimizing blood […]
May 27, 2020 – The Thalassaemia International Federation (TIF) has developed a brief, 10-question survey to assess patients’ knowledge of and perspectives on Gene Therapy for Thalassemia. The survey is available in 6 languages (English, Hindi, Arabic, Italian, Greek and Turkish). For further information and to take the survey, please visit: https://thalassaemia.org.cy/news/surveys/gene-therapy-thalassaemia-version-2-3-a-tif-survey/
April 21, 2020 – TIF has created a Position Statement in which it encourages national health authorities worldwide to include patients with thalassemia and sickle cell disease in the group of patients considered high risk/vulnerable to COVID-19. It is hoped that such a request will lead to increased vigilance and prevention measures on behalf of […]
April 16, 2020 – TIF and the European Hematology Association (EHA) held a webinar today (Thursday, April 16) entitled ”Thalassaemia/SCD and COVID-19: Possible risks and a proposal for a patient pathway during the pandemic”. An expert panel from Italy and Cyprus which includes Dr. Maria D. Capellini, Dr. Raffaella Colombatti, and TIF Executive Director Dr. Androulla Eleftheriou, shared […]
April 14, 2020 – The Thalassaemia International Federation (TIF) has developed this new brochure which provides a listing of many of the vaccines and therapeutic drugs that are currently in development for the treatment/prevention of COVID-19. Download the brochure below.
